Curcumin, a polyphenolic compound derived from the turmeric plant (Curcuma longa), has garnered significant attention for its potential anticancer properties due to its ability to modulate multiple molecular targets involved in cancer development and progression. This chapter provides a comprehensive overview of curcumin’s mechanisms of action in cancer therapy, focusing on its effects on cell proliferation, apoptosis, metastasis, and inflammation. Curcumin exerts its anticancer effects through various signaling pathways, including the suppression of NF-κB, JAK/STAT3, and PI3K/Akt, and the modulation of cell cycle regulators. Despite its promising anticancer potential, curcumin faces challenges in clinical applications due to its poor bioavailability, low solubility, and rapid metabolism. To overcome these limitations, innovative drug delivery systems, such as nanoparticles, liposomes, and polymer-based formulations, have been developed to enhance curcumin’s therapeutic efficacy and stability. These systems improve the solubility, targeted delivery, and controlled release of curcumin, thereby maximizing its anticancer effects while minimizing systemic toxicity. Moreover, preclinical and clinical studies assessing curcumin’s clinical potential in combination with other chemotherapeutic agents and its role as an adjuvant in cancer treatment have shown promising results. The chapter concludes by discussing the challenges and future directions of curcumin-based therapies, including the need for further clinical trials to establish optimal dosage, formulation, and therapeutic regimens and the potential for curcumin to be integrated into personalized cancer treatments.